Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …

The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …

The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …

Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …

Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …

Patients with EGFR-mutant lung cancer derive significant therapeutic benefit from treatment
with EGFR tyrosine kinase inhibitors (TKI). Unfortunately, acquired resistance is an …